The study provides insights into whether vaccines will need matching to future SARS-CoV2 variants.

Friday, February 4, 2022 Original mRNA-1273 Boost Provides Protection Equal to Omicron-Specific Boost The original mRNA-1273 COVID-19 vaccine, developed by NIAID and Moderna scientists, performed equally well when compared to an mRNA-Omicron specific booster in animal studies. NIAID scientists and colleagues, in a study not yet peer reviewed but posted online because of its timeliness, tested both booster vaccines in animals roughly nine months after the animals had received two mRNA-1273 doses. Both boosts provided comparable increase in neutralizing antibodies against Omicron and high-level protection in the lungs against an Omicron challenge. The study affirmed in the animals what has been observed in people, that boosting with mRNA-1273 protects the lungs against severe infection by Omicron. The study provides insights into whether vaccines will need matching to future SARS-CoV2 variants. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107